Aplus Asset Advisor Co. Ltd Overview
A Plus Asset Advisor is an independent insurance general agency (GA): a corporate insurance agency that is not owned by any insurer. It distributes life and non-life policies from roughly 34–35 partner insurers through a contracted salesforce that reached 8,897 planners in mid-2026. It was the first GA to list on KOSPI (2020). It earns commissions from insurers rather than underwriting risk, which makes it a capital-light, fee-based distributor. Its economics are therefore driven by planner headcount, productivity, contract persistency and commission regulation. Around this core the founder built a "Total Life Care" group: funeral and pre-need services (A+Life), real-estate brokerage (A+Realty), healthcare services, IT, and, since 2023, KOSDAQ-listed diagnostics maker Nanoentek. Revenue grew from KRW 258bn (FY2021) to KRW 682.5bn (FY2025). Since late 2025, governance has been the main investment debate. Activist Align Partners now owns about 21% and is pressing for refocus on the core GA business, disposal of non-core assets and board independence [S1][S7][S10][S12].
What the company does
A Plus Asset Advisor is a corporate insurance agency (법인보험대리점, GA). Insurers pay it commissions to sell their products through planners registered to the company. Unlike an insurer's captive (exclusive) salesforce, a GA can sell competing products from many carriers. That lets it present side-by-side comparisons to customers, which is the core of its "insurance department store" positioning. At its 2020 IPO the company said it compared and sold products from 35 insurers. It reported approximately 1.09 million customers and about 1.88 million in-force contracts excluding auto insurance (August 2020) [S21]. Later descriptions cite 34 partner insurers across life and non-life lines [S36].
The company's own self-description in Korean disclosures, as summarised by data providers, has three parts: an independent sales platform not tied to any carrier, a nationwide planner network, and an extension into comprehensive asset-management advice [S1]. An offer document cited in coverage of the 2025 tender offer describes the company's role as comparing products' coverage, expense loadings, investment returns and prices from the customer's point of view, and placing them through its planners on consignment from partner insurers [S10].
Business model and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue type | Almost entirely commission/fee revenue from insurers. Product sales (diagnostic devices via Nanoentek) and service fees (funeral, real-estate brokerage) are a minority. |
| Product vs. service vs. subscription vs. licensing | Service (distribution commissions) dominates. Product revenue arrived with Nanoentek's consolidation from FY2024. Pre-need funeral contracts at A+Life have a subscription-like instalment structure. No licensing revenue identified. |
| Commission structure | Upfront (first-year) acquisition commissions, renewal/maintenance commissions, and insurer performance incentives ("시책"). These are subject to the "1,200% rule", which caps first-year commission at 12× the monthly premium. The cap has applied to insurer-to-GA payments since 2021, and from 1 July 2026 also to GA-to-planner payments [S23]. |
| Cost structure | Commissions paid out to planners are the dominant expense. Valueline's breakdown shows FY2025 selling, general and administrative expenses (SG&A) of KRW 653bn against revenue of KRW 682.5bn [S4]. |
| Capital intensity | Low. Investment needs are mainly IT (sales-support systems), branch fit-outs, leases and planner recruitment incentives. |
| Revenue recognition sensitivity | Brokers note that under the 1,200% rule part of the revenue is deferred, while some selling costs are recognised when paid. This mismatch made reported operating profit volatile after 2021 [S24]. |
Value chain position
The company sits in the distribution link of Korea's insurance value chain:
-
Insurers (manufacturers) develop and underwrite products.
-
GAs and other channels (captive agents, bancassurance, telemarketing, online) sell them.
The industry calls the separation of product manufacturing and sales "제판분리". Large insurers have increasingly spun off their salesforces into subsidiary GAs, Hanwha Life Financial Services being the leading example. This has enlarged the GA channel but also brought insurer-affiliated competitors into it [S26].
Customer types and end-markets
Retail households: the core market, buying protection products (whole life, critical illness, health, cancer, dementia, children's insurance) and savings and pension products.
Partner insurers: effectively the company's revenue counterparties (34–35 life and non-life carriers).
Group / non-core end-markets: funeral and pre-need (A+Life); senior care (A+ Hyodam Lifecare); real-estate brokerage and investment (A+Realty); healthcare services (AAI Healthcare); diagnostics and life-science instruments, sold mostly abroad (Nanoentek); IT and digital (Fine Lab); and loan brokerage (A+ Mortgage) [S18].
Independent characterisation
Stripped of the "Total Life Care" branding, the group is a mid-sized, high-growth, regulation-sensitive insurance distributor with a conglomerate overlay. In FY2025 the parent GA generated about 88% of consolidated revenue (separate revenue KRW 601.3bn vs. consolidated KRW 682.5bn) [S2][S1].
Non-GA subsidiaries added a net KRW 3.3bn to consolidated profit in FY2025 (separate net income KRW 21.3bn; consolidated KRW 24.6bn) [S17]. However, they absorb meaningful capital: non-controlling interests of KRW 91.5bn sit on the balance sheet, largely reflecting Nanoentek's outside shareholders [S5].
The investment case therefore rests on three things: GA planner productivity, how the business absorbs commission regulation, and capital allocation and governance. The activist campaign of 2025–26 targets exactly that last point.
Strategy
Stated strategic themes
-
Grow the core GA through salesforce scale and quality. The organisation expanded to 8,897 planners (+28.8% YoY). Management emphasises protection-type products, planner retention and contract persistency as key management indicators [S7].
-
Dual channel model. Direct (corporate-type) branches are complemented by branch-type independent profit centres, announced in 2022, to gain scale economies. The 2022 targets were 15,000 planners within five years, and 5,000 high-productivity planners plus 10,000 branch-type planners by 2027 [S20].
-
"Total Life Care" platform. The group's three future pillars are finance, living and health. Insurance is to be linked with funeral and senior care, real estate, healthcare services and, since 2023, bio and diagnostics [S18].
-
Respond to regulatory change. Management says it is building "sustainable growth" ahead of the commission reform and changes in financial distribution [S7].
-
Shareholder return and governance (2026).
-
Value-up plan announced 1 Apr 2026.
-
First execution: KRW 7bn buyback, with all shares to be cancelled.
-
A comprehensive value-up programme including governance improvements was promised for 2H26 [S8][S7].
-
Initiative register (last 24 months)
| Date | Initiative | Detail / target | Source |
|---|---|---|---|
| Jun 2025 | Ownership realignment | Financial investor exits half its stake; founder's sons receive gifted shares | [S22] |
| Oct 2025 | Nanoentek share exchange | Direct Nanoentek stake raised to 22.63% | [S19] |
| 1 Apr 2026 | Corporate value enhancement plan | — | [S8] |
| 14 Jul 2026 | KRW 7bn buyback trust | ~647,548 shares; trust runs to 13 Jan 2027; all shares to be cancelled | [S8] |
| 2H 2026 (pending) | Comprehensive value-up programme incl. governance | Specific plan to be published in 2H26 and implemented in stages | [S7] |
| Ongoing | Planner organisation expansion | 8,897 planners at Jun 2026 | [S7] |
Medium-term financial targets.
-
No current quantitative guidance (revenue, margin, ROE, payout) was identified.
-
The 2020 IPO targets (group revenue KRW 1 trillion and net income KRW 100bn by 2024) were not achieved. FY2024 actuals were revenue KRW 515.8bn and net income KRW 10.1bn [S21][S1].
Products & Services
Core GA (parent) — insurance distribution
| Offering | Description | Target customer | Pricing / revenue model | Source |
|---|---|---|---|---|
| Life protection products (multiple carriers) | Whole life, including the short-pay whole life products that drove 2023 sales, plus critical illness and children's policies | Retail households | First-year and renewal commissions plus insurer incentives, under the 1,200% cap | [S24] |
| Long-term non-life (health) products | Health, cancer, dementia and similar long-term protection from non-life carriers. Management emphasised protection products in 1H26. | Retail | Commissions | [S7] |
| Savings and pension insurance | Annuity and savings-type life policies | Retail | Commissions | [S1] |
| Auto and general insurance | Sold but excluded from the 1.88M in-force contract count at IPO | Retail | Commissions | [S21] |
| Product comparison and advice | Comparison across ~34–35 carriers. Large GAs must present at least three comparable products; from Jul 2026 they must also show the commission grade (5 tiers) and ranking of recommended products. | Retail | Embedded in commissions | [S21], [S23] |
| CFP Center / Financial Clinic Center | Advisory units led by certified financial planners providing tailored portfolios; monthly asset-management seminars (≈30,000 attendees cumulative by 2011) | Mass-affluent | Advisory feeds product sales | [S30] |
| "Bopl" (보험플러스) app | Insurance-coverage analysis app with AI functionality and automated payment, described at IPO | Retail / planners | Supports sales | [S21] |
| "Wepl" app | Healthcare app with 24-hour health consultation and personalised reports; launch planned for Jan 2021 per IPO coverage | Retail | — | [S21] |
| Sales channels | Direct (corporate-type) branches plus branch-type (independent profit-centre) channel since 2022 | Planners | Commission splits | [S20] |
Commission rates by product, carrier mix and life vs. non-life revenue split were not publicly disclosed in the sources reviewed.
Group subsidiaries
| Offering | Entity | Description | Source |
|---|---|---|---|
| Funeral and pre-need contracts | A+Life | Funeral services sold on instalment membership; also acts as group holding vehicle (lead buyer of Nanoentek) | [S18], [S30] |
| Senior / long-term care | A+ Hyodam Lifecare | Elderly care services | [S18] |
| Real-estate brokerage and PB services | A+Realty | Comprehensive real-estate private-banking services and group property investment. Brokered the KRW 430bn A+ Asset Tower sale. | [S18], [S20] |
| Healthcare services | AAI Healthcare | Health-management services using a network of ~11,000 hospitals and in-house nurse counsellors | [S18] |
| Digital IT | Fine Lab | Group IT and digital platform development | [S18] |
| Loan brokerage | A+ Mortgage | Loan intermediation | [S18] |
| In-vitro diagnostics and life-science instruments | Nanoentek | Products built on lab-on-a-chip technology combining MEMS and microfluidics. Revenue is largely export. Product lines per the company's catalogue (not re-verified here): automated cell counters, live-cell imaging and point-of-care immunoassay platforms. | [S18] |
Financial Narrative
Income statement
Sources:
-
Revenue, operating income, total net income and margins: DART-based [S1].
-
EBITDA, pre-tax income, tax, FY2025 attributable net income and EPS: Valueline [S4].
-
FY2021–FY2023 attributable net income and EPS: SK Securities [S24]; FY2021 and FY2023 attributable net income derived from EPS × shares.
-
DPS: [S3].
Not available: diluted EPS (no material dilutive instruments identified), and gross profit, which is not meaningful because no cost of sales is reported for the core business.
Revenue CAGR (FY2021–FY2025): (6,825 / 2,580)^(1/4) − 1 ≈ 27.5% (computed).
Trend commentary.
2021–22 (regulatory trough): Applying the 1,200% rule to insurer-to-GA commissions in 2021 cut first-year revenue while commission and operating costs stayed. Revenue fell 9.5% and operating profit collapsed to KRW 5.7bn in FY2021 and KRW 1.4bn in FY2022 [S25][S1].
FY2022 headline profit was non-operating: Net income of KRW 65.5bn came from the KOCREF 31 REIT liquidation (KRW 76.6bn of equity-method gains in 1H22 alone) [S20].
2023–24 (IFRS 17 sales boom): Insurers competed hard for new business under IFRS 17, especially short-pay whole life and children's products. Insurers also raised performance incentives that sit outside the 1,200% cap. Revenue rose 29.6% in FY2023 and 47% in FY2024; operating profit reached KRW 31.6bn [S24][S1].
FY2024 net income (KRW 10.1bn) was depressed: by a KRW 22.7bn equity-method loss in 4Q24 visible in Valueline's trailing data [S4], around the time Nanoentek moved from associate to subsidiary.
FY2025: Revenue grew 32.3% to KRW 682.5bn. Operating profit dipped 7% to KRW 29.3bn as commission and incentive costs rose faster than revenue. Net income recovered to KRW 24.7bn, up 144.8% [S8].
1H26 inflection: Revenue grew 18.4% while operating profit rose 59.3% and net income 80.9%, so margins expanded. Trailing-twelve-month (TTM) operating profit to Jun-2026 was KRW 39.0bn on revenue of KRW 742.3bn (5.3% margin) [S7][S4].
Interim periods (FY2026 year to date)
Sources: 1H26 and 1Q26 [S7][S8]. 1H25 back-calculated from reported growth rates. 2Q26 derived as 1H26 minus 1Q26. 1Q26 was a record quarterly revenue [S8].
Balance sheet
Sources: [S5].
At 30 June 2026 [S5]:
-
Total assets KRW 544.6bn
-
Cash KRW 34.6bn plus short-term financial assets KRW 84.3bn
-
Borrowings KRW 26.3bn
-
Owners' equity KRW 183.6bn
-
Book value per share KRW 8,120
Cash flow
Sources: OCF [S6]; FCF [S1]; dividends and buybacks [S3]. TTM operating cash flow to Jun-2026 was KRW 50.8bn [S6]. The KRW 7bn buyback was authorised in Jul 2026, i.e. FY2026 [S8].
Ratios
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Activity | A+ Asset stake (FY2025 business report unless noted) | Latest total assets (KRW 100M) | Latest net income (KRW 100M) | Source |
|---|---|---|---|---|---|
A Plus Asset Advisor (parent) | Independent GA | — | — | 213 (separate FY2025) | [S17] |
Nanoentek Co., Ltd. (KOSDAQ 039860) | Lab-on-a-chip diagnostics and life-science instruments | 25.73% direct; further shares held via A+Life and AAI Healthcare (consolidated) | 980 | 15.8 | [S2], [S18] |
A+Life Co., Ltd. | Funeral / pre-need services | 52.23% | 1,190 | 6.6 | [S2] |
A+Realty Co., Ltd. | Real-estate brokerage, consulting and investment | 88.11% | 474 | -0.59 | [S2] |
Fine Lab Co., Ltd. | Digital / IT services | 100% | 18.2 | 1.2 | [S2] |
AAI Healthcare Co., Ltd. | Healthcare services (network of ~11,000 hospitals cited in 2023) | — | — | — | [S2], [S18] |
A+ Hyodam Lifecare | Senior / long-term care | — | — | — | [S18] |
A+ Mortgage | Loan brokerage | — | — | — | [S18] |
“—” = not publicly disclosed.
Revenue by Segment (KRW) and Revenue by Segment (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Consolidated revenue (KRW 100M) | 3,509 | 5,158 | 6,825 |
Parent GA separate revenue (KRW 100M) | — | — | 6,013 |
Non-parent revenue, net of eliminations (KRW 100M) | — | — | 812 |
Parent GA share of consolidated revenue (%) | — | — | 88.1 |
Parent separate net income (KRW 100M) | — | — | 213 |
Consolidated net income (KRW 100M) | 117 | 101 | 247 |
Subsidiary net contribution to net income (KRW 100M) | — | — | 33 |
Income Statement (KRW) and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW 100M) | 2,580 | 2,707 | 3,509 | 5,158 | 6,825 |
Revenue growth YoY (%) | -9.5 | 4.9 | 29.6 | 47.0 | 32.3 |
Operating income (KRW 100M) | 57 | 14 | 126 | 316 | 293 |
Operating margin (%) | 2.2 | 0.5 | 3.6 | 6.1 | 4.3 |
EBITDA (KRW 100M) | — | — | — | — | 576 |
EBITDA margin (%) | — | — | — | — | 8.4 |
Pre-tax income from continuing ops (KRW 100M) | — | — | — | — | 287 |
Income tax (KRW 100M) | — | — | — | — | 55 |
Net income, total (KRW 100M) | 154 | 655 | 117 | 101 | 247 |
Net margin (%) | 6.0 | 24.2 | 3.3 | 2.0 | 3.6 |
Net income attributable to owners (KRW 100M) | 121 | 503 | 102 | — | 221 |
EPS basic, attributable (KRW) | 535 | 2,226 | 451 | — | 979 |
Dividend per share (KRW) | 150 | 200 | 200 | 200 | 300 |
Income Statement (KRW)
| Metric | 1H2025 | 1Q2026 | 2Q2026 | 1H2026 |
|---|---|---|---|---|
Revenue (KRW 100M) | 3,257 | 1,866 | 1,990 | 3,856 |
Operating income (KRW 100M) | 163 | 159 | 101 | 260 |
Net income (KRW 100M) | 123 | — | — | 222 |
Balance Sheet (KRW)
| Metric (KRW 100M) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets | 3,453 | 3,729 | 4,793 | 5,153 |
Current assets | 2,039 | 2,074 | 3,121 | 3,309 |
Cash & cash equivalents | 243 | 77 | 262 | 181 |
Short-term financial assets | 1,133 | 876 | 1,250 | 1,101 |
Total borrowings | 131 | 230 | 327 | 283 |
Short-term borrowings incl. current portion of long-term debt | 26 | 230 | 270 | 267 |
Long-term borrowings | 105 | 0 | 57 | 17 |
Net debt (negative = net cash) | -1,245 | -724 | -1,185 | -998 |
Total liabilities | 1,592 | 1,833 | 2,355 | 2,541 |
Equity attributable to owners | 1,458 | 1,504 | 1,505 | 1,697 |
Non-controlling interests | 403 | 392 | 932 | 915 |
Total equity | 1,861 | 1,895 | 2,438 | 2,612 |
Goodwill | 0 | 0 | 117 | 112 |
Goodwill & intangibles | 45 | 43 | 227 | 214 |
Investment property | 123 | 371 | 369 | 369 |
Working capital (current assets − current liabilities) | 1,260 | 1,053 | 1,659 | 1,695 |
Cash Flow (KRW)
| Metric (KRW 100M) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow | — | — | — | — | 318 |
Capex (implied: OCF − FCF) | — | — | — | — | 99 |
Free cash flow | — | — | — | — | 219 |
Dividends declared for the fiscal year | 34 | 45 | 45 | 45 | 68 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, attributable (%) | 12.6 | 41.3 | 6.9 | 1.6 | 13.8 |
ROA (%; total net income ÷ period-end assets) | — | 19.0 | 3.1 | 2.1 | 4.8 |
Current ratio (x) | — | 2.62 | 2.03 | 2.13 | 2.05 |
Debt to equity (%; borrowings ÷ total equity) | — | 7.0 | 12.1 | 13.4 | 10.8 |
Liabilities to equity (%) | — | 85.5 | 96.7 | 96.6 | 97.3 |
Asset turnover (x; revenue ÷ period-end assets) | — | 0.78 | 0.94 | 1.08 | 1.32 |
Interest coverage (x; operating income ÷ interest expense) | — | — | — | — | 9.5 |
Net debt to EBITDA (x; negative = net cash) | — | — | — | — | -1.7 |
Dividend payout (%; declared dividends ÷ total net income) | 28 | 9 | 44 | 182 | 31 |
Region Overview
| Region | FY2025 |
|---|---|
South Korea, parent GA separate revenue (KRW 100M) | 6,013 |
Valuation Multiples (KRW) and Valuation Multiples (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Year-end share price (KRW) | — | 4,840 | 4,335 | 4,410 | 8,940 |
Year-end market cap (KRW 100M) | — | 1,094 | 980 | 997 | 2,021 |
Year-end P/B (x) | — | — | 0.65 | 0.66 | 1.19 |
Dividend per share (KRW) | 150 | 200 | 200 | 200 | 300 |
Return / level
| Return / level | Value | Basis / source |
|---|---|---|
Last close | KRW 11,790 (15-Oct-2026) | [S5] |
52-week range | KRW 5,840 – 14,780 | [S1]. Investing.com shows KRW 5,600 – 14,990 [S42]; vendor discrepancy. |
1-year price return | +87.7% to 7-Oct-2026 | [S1] |
~3-year price return | ≈ +188% (KRW 4,100 on 8-Sep-2023 → KRW 11,790) | Computed from [S24][S5] |
~5-year price return | ≈ +14% (KRW 10,300 on 19-Nov-2021 → KRW 11,790) | Computed from [S25][S5] |
Since IPO | +57% vs. KRW 7,500 offer price | Computed from [S21] |
Valuation Multiples
| Multiple | A Plus Asset Advisor | Incar Financial Service (late Aug 2026) | Notes |
|---|---|---|---|
P/E (TTM, attributable) | 8.7× | 6.2× | A+ TTM EPS KRW 1,356 [S4]; Incar per [S28] |
P/B | 1.45× | 2.12× | A+ BPS KRW 8,120 at Jun-2026 [S5] |
EV/EBITDA (TTM) | ≈3.6× | Not computed | EV ≈ market cap 2,665 + borrowings 263 + NCI 915 − cash and ST financial assets 1,189 = ≈KRW 265bn; TTM EBITDA KRW 74.2bn [S4][S5] |
EV/Sales (TTM) | ≈0.36× | Not computed | TTM revenue KRW 742.3bn [S4] |
Dividend yield | 2.5% | — | KRW 300 ÷ KRW 11,790 |
Analyst Conclusions
Guidance and expectations
Management guidance: No quantitative guidance. Management's qualitative messages are: continued planner expansion, a focus on protection products and persistency, a 2H26 comprehensive value-up and governance programme, and cancellation of the 2026 buyback shares [S7][S8].
Consensus: None available.
Run-rate (not guidance): TTM figures to Jun-2026 are revenue KRW 742.3bn, operating profit KRW 39.0bn and attributable net income KRW 30.7bn [S4].
Bull case
-
Operating leverage is visible. 1H26 operating profit +59% on revenue +18%. ROE has recovered from 1.6% (FY2024) to 18.0%, close to Incar's level of returns. Yet the stock trades at 1.45× book vs. Incar's 2.12× [S7][S14][S28].
-
Capital is ready to be returned. About KRW 100bn of net cash, a first buyback-and-cancel, and a pending governance programme. A 20.88% activist holder gives a credible catalyst [S5][S8][S2].
-
Scale is growing structurally. Planners +28.8% YoY in a channel taking share from captive agents [S7][S26].
Bear case
-
Reform threatens the recruitment model. From Jul 2026 all planner support counts within the 1,200% cap, and from 2027 commissions are paid over 4 and later 7 years. This could slow headcount growth and lift churn just as growth is being priced in [S23].
-
Thin margins. A 4.3% operating margin (FY2025) leaves little buffer against incentive-cost spikes [S1].
-
Governance discount may persist. Management won every AGM vote, the founder's group is increasing its stake, and Nanoentek ties up capital at minimal returns [S15][S16][S19].
Catalysts and monitorables (next 12 months)
3Q26 results (expected mid-Nov 2026): first quarter fully under the 1,200% rule for GA planners.
2H26 value-up programme: look for a formal payout or total-return policy, board-structure changes, and treatment of Nanoentek and listed equities.
Buyback: completion of the KRW 7bn programme (trust ends 13 Jan 2027) and the cancellation resolution.
January 2027: start of the commission spread and its effect on planner recruitment and retention.
FY2026 dividend (declared ~Mar 2027): and the 2027 AGM: renewed activist proposals, and the mandatory two separately elected audit-committee members for large listed companies [S43].
Ownership: further moves by the founder's group, Align or insurance-sector holders.
Analyst verdict
A Plus Asset Advisor has become a more profitable distributor than its five-year record suggests. FY2021–FY2024 combined three distortions: a regulatory trough, a one-off real-estate windfall and a subsidiary-related write-down. Those obscured the underlying trend, which is a GA that has nearly tripled revenue since FY2021 and is now converting growth into earnings. 1H26 operating profit rose 59%, and annualised ROE reached 18%.
At about 8.7× TTM earnings, 1.45× book and roughly 3.6× EV/EBITDA, with ~KRW 100bn of net cash, the valuation already discounts a good deal of regulatory and governance risk. It still sits at a discount to the closest listed peer, Incar.
The debate is no longer whether the core business works. It is whether the 2026–2029 commission reform will cap its growth, and whether the controlling shareholder will let outside shareholders capture the cash it generates.
On the first question, the evidence is incomplete. The 1,200% planner cap started only in July 2026 and the spread begins in 2027. Investors should treat 2H26–1H27 planner counts, retention and incentive costs as the decisive data.
On the second, the record is mixed:
-
Management beat the activist at the AGM and the founder's group is buying.
-
It has also raised the dividend 50%, launched the first buyback-and-cancel, and committed to a governance programme.
Our assessment is that the shares offer asymmetric but conditional upside. A credible 2H26 value-up programme could narrow the discount to peers: a formal payout policy, a plan for Nanoentek and the listed-equity portfolio, and stronger board independence. A merely cosmetic programme, combined with a reform-driven slowdown in planner growth, would likely return the stock towards book-value multiples seen before the activist entry.
The key monitorables are the 3Q26 margin, the content of the value-up announcement and January 2027 planner retention.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | 2025 compensation | Source |
|---|---|---|---|---|
Kwak Geun-ho (곽근호) | Chairman and co-CEO; founder; largest shareholder | Founded the company in 2007. | KRW 1.36bn (only individually disclosed director pay). Align described his pay as mostly fixed, not performance-linked, and a large share of total registered-director pay. | [S2], [S12] |
Hwang Seung-mok (황승목) | Co-CEO | Appointment date and background not publicly verified in sources reviewed | Below the KRW 500M individual disclosure threshold or not disclosed | [S7] |
Park Kyung-soon (박경순) | Former CEO at IPO (2020); now listed as an unregistered executive holding 0.35% | Fronted the 2020 IPO roadshow | — | [S21], [S2] |
Cho Kyu-nam (조규남) | Unregistered executive; 0.47% holding | — | — | [S2] |
Baek Hong-ki (백홍기) | Executive vice president; bought 2,000 shares in Oct 2025 (0.15% holding) | — | — | [S31] |
Lee Je-kyung (이제경) | Outside director (elected Mar-2026 AGM, management nominee) | — | — | [S15] |
Two audit-committee outside directors (management nominees) | Separately elected audit-committee members (elected Mar 2026) | — | — | [S15] |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake (%) | Date / basis | Source |
|---|---|---|---|
Kwak Geun-ho | 20.20 | FY2025 year-end | [S2] |
Kwak Tae-min (related party) | 2.68 | FY2025 | [S2] |
Kwak Tae-ik (related party) | 2.25 | FY2025 | [S2] |
Kim Kyung-ae (related party) | 0.77 | FY2025 | [S2] |
Cho Kyu-nam (unregistered executive) | 0.47 | FY2025 | [S2] |
Shin Da-ye (related party) | 0.40 | FY2025 | [S2] |
Park Kyung-soon (unregistered executive) | 0.35 | FY2025 | [S2] |
Other related parties (5 individuals) | 0.58 | FY2025 | [S2] |
Largest shareholder and related parties, total | 27.94 → 29.80 | FY2025 → 5-Aug-2026 filing | [S2] |
Align Partners Asset Management (incl. funds) | 20.88 | 2-Jul-2026 large-holding report (18.05% in Feb 2026) | [S2], [S12] |
National Pension Service | 0.07 | End-2024 | [S2] |
Minority shareholders (5,853 holders) | 48.1 | FY2025 | [S2] |
Competitive Landscape
Key Competitors
| Competitor | Type | Scale indicator | Source |
|---|---|---|---|
Hanwha Life Financial Services | Insurer-owned GA (Hanwha Life spin-off, 2021) | FY2025 revenue KRW 2.44 trillion; net income KRW 115.8bn; 34,608 planners incl. subsidiary GAs | [S26] |
Incar Financial Service (KOSDAQ 211050) | Independent listed GA | FY2025 revenue ≈KRW 1.02 trillion; operating profit KRW 94.8bn; net income KRW 71.0bn; 16,858 planners (end-2024) | [S28], [S27] |
GA Korea | Independent GA | 16,449 planners (end-2024); first-time entrant to Korea's top-500 companies list in 2026 | [S27], [S37] |
Global Financial Sales (글로벌금융판매) | Independent GA | 13,088 planners (end-2024) | [S27] |
KGA Asset (케이지에이에셋) | Independent GA | Top-tier GA recruiting aggressively | [S38] |
Prime Asset (프라임에셋) | Independent GA | Top-tier GA recruiting aggressively | [S38] |
PeopleLife | GA (Hanwha LFS subsidiary) | Acquired by Hanwha LFS | [S39] |
IFC Group | GA (Hanwha LFS subsidiary) | Acquired by Hanwha LFS | [S39] |
Samsung Life Financial Services | Insurer-owned GA | — | — |
Insurers' captive salesforces and bancassurance | Competing channels | — | — |
Peer Comparison FY2025
| Metric | A Plus Asset Advisor | Incar Financial Service | Hanwha Life Financial Services | GA Korea |
|---|---|---|---|---|
Revenue (KRW 100M) | 6,825 | 10,217 | 24,397 | — |
Revenue growth (%) | 32.3 | 22.8 | 15.6 | — |
Operating margin (%) | 4.3 | 9.3 | — | — |
Net margin (%) | 3.6 | 6.9 | 4.7 | — |
Planners (latest) | 8,897 | 16,858 | 34,608 | 16,449 |
R&D intensity (%) | 0.5 | — | — | — |
P/B (x, latest) | 1.45 | 2.12 | — | — |



